Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in Primary Immune Thrombocytopenia (ITP)
NCT06853444Phase 2Recruiting
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- May 2025
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ESG206 in primary immune thrombocytopenia (ITP) (4 arms), sponsored by Shanghai Escugen Biotechnology Co., Ltd. Primary endpoints: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events at 24 weeks and Confirmed response rate at 25 weeks. Started May 2025; status: recruiting.
02
Drugs
ESG206
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06853444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853444.